title: Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
abstract: Tumor necrosis factor-alpha (TNF alpha) and interleukin-6 (IL-6) are products of activated monocytes/macrophages with anti-tumor activity. Liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) is a potent monocyte/macrophage activator. Sera from cats after intravenous L-MTP-PE administration showed TNF alpha activity using a WEHI-164 cell cytotoxicity assay and IL-6 activity using an IL-6 dependent mouse 7TD1 hybridoma cell proliferation assay. Serum TNF alpha activity peaked at 2 hours after L-MTP-PE administration. Significant differences from lipid-equivalent controls were observed at 2 and 3 hours (P < 0.05). Neutralization of serum TNF alpha activity was accomplished with serial dilutions of rhTNF alpha monoclonal antibody. Serum IL-6 activity peaked at 3 hours after L-MTP-PE administration. Significant differences from lipid-equivalent controls were observed at 2, 3, and 4 hours (P < 0.05). Neutralization of serum IL-6 activity was not achieved with goat anti-rhIL-6 polyclonal antibody. Intravenous L-MTP-PE, but not lipid-equivalent, induces serum TNF alpha and IL-6 activity in normal cats.
authors.affiliation: Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville 32610-0126, USA.
authors.forename: L E
authors.initials: LE
authors.lastname: Fox
authors.forename: R R
authors.initials: RR
authors.lastname: King
authors.forename: F
authors.initials: F
authors.lastname: Shi
authors.forename: I D
authors.initials: ID
authors.lastname: Kurzman
authors.forename: E G
authors.initials: EG
authors.lastname: MacEwen
authors.forename: P S
authors.initials: PS
authors.lastname: Kubilis
mesh_terms: D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001772:Blood Cell Count / Q000187:drug effects; D002415:Cats; D004337:Drug Carriers; D005260:Female; D006041:Goats / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007202:Indicators and Reagents; D015850:Interleukin-6 / Q000096:biosynthesis*; D008081:Liposomes; D008297:Male; D051379:Mice; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D007074:Immunoglobulin G; D007202:Indicators and Reagents; D015850:Interleukin-6; D008081:Liposomes; D010714:Phosphatidylethanolamines; D014409:Tumor Necrosis Factor-alpha; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine